The IgA1 immune complex-mediated activation of the MAPK/ERK kinase pathway in mesangial cells is associated with glomerular damage in IgA nephropathy

Kidney International

Volumn 82, Issue 12, 2012, Pages 1284-1296

  Tamouza, Houda ^a,b   Chemouny, Jonathan M ^a,b,c   Raskova Kafkova, Leona ^d   Berthelot, Laureline ^a,b   Flamant, Martin ^a,b,c   Demion, Marie ^a,b   Mesnard, Laurent ^a,e,f   Paubelle, Etienne ^a,b   Walker, Francine ^c   Julian, Bruce A ^d,g   Tissandié, Emilie ^a,b   Tiwari, Meetu K ^a,b   Camara, Niels O S ^h   Vrtovsnik, François ^a,b,c   Benhamou, Marc ^a,b   Novak, Jan ^d   Monteiro, Renato C ^a,b,c   Moura, Ivan C ^a,b  

^a INSERM   (France)

^b UNIVERSITÉ PARIS DESCARTES   (France)

^c BICHAT HOSPITAL   (France)

^d University of Alabama at Birmingham   (United States)

^e HÔPITAL TENON   (France)

^f SORBONNE UNIVERSITÉ   (France)

^g and Clinical Center   (United States)

^h UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

IgA; IgA deposition; IgA nephropathy

Indexed keywords

CALCIUM; CD71 ANTIGEN; CYTOKINE; IMMUNOGLOBULIN A1; IMMUNOGLOBULIN G; INTERLEUKIN 6; MAMMALIAN TARGET OF RAPAMYCIN; MITOGEN ACTIVATED PROTEIN KINASE; PHOSPHATIDYLINOSITOL 3 KINASE;

ARTICLE; CALCIUM SIGNALING; CELL ACTIVATION; CELL PROLIFERATION; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE RELEASE; ENZYME ACTIVATION; HUMAN; HUMAN CELL; HUMAN TISSUE; HYPERTENSION; IMMUNOGLOBULIN A NEPHROPATHY; IN VITRO STUDY; KIDNEY BIOPSY; KIDNEY INJURY; MESANGIUM CELL; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEINURIA; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM;

EID: 84870582926     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1038/ki.2012.192     Document Type: Article

References (66)

1. Berger J, Hinglais N. [Intercapillary deposits of IgA-IgG]. J Urol Nephrol (Paris) 1968; 74: 694-695.
2. Monteiro RC, Moura IC, Launay P et al. Pathogenic significance of IgA receptor interactions in IgA nephropathy. Trends Mol Med 2002; 8: 464-468.
3. Coppo R, D'Amico G. Factors predicting progression of IgA nephropathies. J Nephrol 2005; 18: 503-512.
4. Locatelli F, Marcelli D, Comelli M et al. Proteinuria and blood pressure as causal components of progression to end-stage renal failure. Northern Italian Cooperative Study Group. Nephrol Dial Transplant 1996; 11: 461-467.
5. Stoycheff N, Pandya K, Okparavero A et al. Early change in proteinuria as a surrogate outcome in kidney disease progression: a systematic review of previous analyses and creation of a patient-level pooled dataset. Nephrol Dial Transplant 2011; 26: 848-857.
6. Fassett RG, Venuthurupalli SK, Gobe GC et al. Biomarkers in chronic kidney disease: a review. Kidney Int 2011; 80: 806-821.
7. Kreisberg JI. Contractile properties of the glomerular mesangium. Fed Proc 1983; 42: 3053-3057.
8. Michael AF, Kim Y. The glomerular mesangium. Am J Kidney Dis 1988; 12: 393-396.
9. Schlondorff D, Banas B. The mesangial cell revisited: no cell is an island. J Am Soc Nephrol 2009; 20: 1179-1187.
10. Moura IC, Arcos-Fajardo M, Sadaka C et al. Glycosylation and size of IgA1 are essential for interaction with mesangial transferrin receptor in IgA nephropathy. J Am Soc Nephrol 2004; 15: 622-634.
11. Moura IC, Arcos-Fajardo M, Gdoura A et al. Engagement of transferrin receptor by polymeric IgA1: evidence for a positive feedback loop involving increased receptor expression and mesangial cell proliferation in IgA nephropathy. J Am Soc Nephrol 2005; 16: 2667-2676.
12. Yoshioka K. Scaffold proteins in mammalian MAP kinase cascades. J Biochem 2004; 135: 657-661.
13. Masaki T, Stambe C, Hill PA et al. Activation of the extracellular-signal regulated protein kinase pathway in human glomerulopathies. J Am Soc Nephrol 2004; 15: 1835-1843.
14. Burgermeister E, Seger R. MAPK kinases as nucleo-cytoplasmic shuttles for PPARgamma. Cell Cycle 2007; 6: 1539-1548.
15. Cattran DC, Coppo R, Cook HT et al. The Oxford classification of IgA nephropathy: rationale, clinicopathological correlations, and classification. Kidney Int 2009; 76: 534-545.
16. Novak J, Julian BA, Tomana M et al. IgA glycosylation and IgA immune complexes in the pathogenesis of IgA nephropathy. Semin Nephrol 2008; 28: 78-87.
17. Barratt J, Smith AC, Feehally J. The pathogenic role of IgA1 O-linked glycosylation in the pathogenesis of IgA nephropathy. Nephrology (Carlton) 2007; 12: 275-284.
18. Kiryluk K, Moldoveanu Z, Sanders JT et al. Aberrant glycosylation of IgA1 is inherited in both pediatric IgA nephropathy and Henoch-Schonlein purpura nephritis. Kidney Int 2011; 80: 79-87.
19. Moldoveanu Z, Wyatt RJ, Lee JY et al. Patients with IgA nephropathy have increased serum galactose-deficient IgA1 levels. Kidney Int 2007; 71: 1148-1154.
20. Moore JS, Kulhavy R, Tomana M et al. Reactivities of Nacetylgalactosamine- specific lectins with human IgA1 proteins. Mol Immunol 2007; 44: 2598-2604.
21. Suzuki H, Fan R, Zhang Z et al. Aberrantly glycosylated IgA1 in IgA nephropathy patients is recognized by IgG antibodies with restricted heterogeneity. J Clin Invest 2009; 119: 1668-1677.
22. Tomana M, Matousovic K, Julian BA et al. Galactose-deficient IgA1 in sera of IgA nephropathy patients is present in complexes with IgG. Kidney Int 1997; 52: 509-516.
23. Tomana M, Novak J, Julian BA et al. Circulating immune complexes in IgA nephropathy consist of IgA1 with galactose-deficient hinge region and antiglycan antibodies. J Clin Invest 1999; 104: 73-81.
24. Novak J, Tomana M, Matousovic K et al. IgA1-containing immune complexes in IgA nephropathy differentially affect proliferation of mesangial cells. Kidney Int 2005; 67: 504-513.
25. McCubrey JA, Steelman LS, Abrams SL et al. Roles of the RAF/MEK/ERK and PI3K/PTEN/AKT pathways in malignant transformation and drug resistance. Adv Enzyme Regul 2006; 46: 249-279.
26. Liu P, Cheng H, Roberts TM et al. Targeting the phosphoinositide 3-kinase pathway in cancer. Nat Rev Drug Discov 2009; 8: 627-644.
27. Komatsu N, Watanabe T, Uchida M et al. A member of Forkhead transcription factor FKHRL1 is a downstream effector of STI571-induced cell cycle arrest in BCR-ABL-expressing cells. J Biol Chem 2003; 278: 6411-6419.
28. Gomez-Guerrero C, Lopez-Armada MJ, Gonzalez E et al. Soluble IgA and IgG aggregates are catabolized by cultured rat mesangial cells and induce production of TNF-a and IL-6, and proliferation. J Immunol 1994; 153: 5247-5255.
29. Haddad E, Moura IC, Arcos-Fajardo M et al. Enhanced expression of the CD71 mesangial IgA1 receptor in Berger disease and Henoch-Schonlein nephritis: association between CD71 expression and IgA deposits. J Am Soc Nephrol 2003; 14: 327-337.
30. Lepelletier Y, Camara-Clayette V, Jin H et al. Prevention of mantle lymphoma tumor establishment by routing transferrin receptor toward lysosomal compartments. Cancer Res 2007; 67: 1145-1154.
31. Moura IC, Lepelletier Y, Arnulf B et al. A neutralizing monoclonal antibody (mAb A24) directed against the transferrin receptor induces apoptosis of tumor T lymphocytes from ATL patients. Blood 2004; 103: 1838-1845.
32. Remuzzi A, Perico N, Sangalli F et al. ACE inhibition and ANG II receptor blockade improve glomerular size-selectivity in IgA nephropathy. Am J Physiol 1999; 276: F457-F466.
33. Barratt J, Smith AC, Molyneux K et al. Immunopathogenesis of IgAN. Semin Immunopathol 2007; 29: 427-443.
34. Beerman I, Novak J, Wyatt RJ et al. The genetics of IgA nephropathy. Nat Clin Pract Nephrol 2007; 3: 325-338.
35. Gharavi AG, Yan Y, Scolari F et al. IgA nephropathy, the most common cause of glomerulonephritis, is linked to 6q22-23. Nat Genet 2000; 26: 354-357.
36. Kiryluk K, Julian BA, Wyatt RJ et al. Genetic studies of IgA nephropathy: past, present, and future. Pediatr Nephrol 2011; 25: 2257-2268.
37. Gharavi AG, Kiryluk K, Choi M et al. Genome-wide association study identifies susceptibility loci for IgA nephropathy. Nat Genet 2011; 43: 321-327.
38. Nakahara T, Moroi Y, Uchi H et al. Differential role of MAPK signaling in human dendritic cell maturation and Th1/Th2 engagement. J Dermatol Sci 2006; 42: 1-11.
39. Koj A. Initiation of acute phase response and synthesis of cytokines. Biochim Biophys Acta 1996; 1317: 84-94.
40. Johnson GL, Lapadat R. Mitogen-activated protein kinase pathways mediated by ERK, JNK, and p38 protein kinases. Science 2002; 298: 1911-1912.
41. Tamouza H, Vende F, Tiwari M et al. Transferrin receptor engagement by polymeric IgA1 induces receptor expression and mesangial cell proliferation: role in IgA nephropathy. Contrib Nephrol 2007; 157: 144-147.
42. Blank U, Essig M, Scandiuzzi L et al. Mast cells and inflammatory kidney disease. Immunol Rev 2007; 217: 79-95.
43. Gomez-Guerrero C, Hernandez-Vargas P, Lopez-Franco O et al. Mesangial cells and glomerular inflammation: from the pathogenesis to novel therapeutic approaches. Curr Drug Targets Inflamm Allergy 2005; 4: 341-351.
44. .Muller GA, Markovic-Lipkovski J, Frank J et al. The role of interstitial cells in the progression of renal diseases. J Am Soc Nephrol 1992; 2: S198-S205.
45. Lai KN, Leung JC, Chan LY et al. Activation of podocytes by mesangialderived TNF-alpha: glomerulo-podocytic communication in IgA nephropathy. Am J Physiol Renal Physiol 2008; 294: F945-F955.
46. Duque N, Gomez-Guerrero C, Egido J. Interaction of IgA with Fc a receptors of human mesangial cells activates transcription factor nuclear factor-k B and induces expression and synthesis of monocyte chemoattractant protein-1, IL-8, and IFN-inducible protein 10. J Immunol 1997; 159: 3474-3482.
47. Lai KN, Chan LY, Tang SC et al. Mesangial expression of angiotensin II receptor in IgA nephropathy and its regulation by polymeric IgA1. Kidney Int 2004; 66: 1403-1416.
48. Han Y, Runge MS, Brasier AR. Angiotensin II induces interleukin-6 transcription in vascular smooth muscle cells through pleiotropic activation of nuclear factor-k B transcription factors. Circ Res 1999; 84: 695-703.
49. Ruiz-Ortega M, Bustos C, Hernandez-Presa MA et al. Angiotensin II participates in mononuclear cell recruitment in experimental immune complex nephritis through nuclear factor-k B activation and monocyte chemoattractant protein-1 synthesis. J Immunol 1998; 161: 430-439.
50. Komers R, Schutzer W, Xue H et al. Effects of p38 mitogen-activated protein kinase inhibition on blood pressure, renal hemodynamics, and renal vascular reactivity in normal and diabetic rats. Transl Res 2007; 150: 343-349.
51. Ljutic D, Kes P. The role of arterial hypertension in the progression of nondiabetic glomerular diseases. Nephrol Dial Transplant 2003; 18(Suppl 5): v28-v30.
52. Becher UM, Endtmann C, Tiyerili V et al. Endothelial damage and regeneration: the role of the renin-angiotensin-aldosterone system. Curr Hypertens Rep 2011; 13: 86-92.
53. Helou CM, Imbert-Teboul M, Doucet A et al. Angiotensin receptor subtypes in thin and muscular juxtamedullary efferent arterioles of rat kidney. Am J Physiol Renal Physiol 2003; 285: F507-F514.
54. Praga M, Gutierrez E, Gonzalez E et al. Treatment of IgA nephropathy with ACE inhibitors: a randomized and controlled trial. J Am Soc Nephrol 2003; 14: 1578-1583.
55. Haller H, Ito S, Izzo Jr JL et al. Olmesartan for the delay or prevention of microalbuminuria in type 2 diabetes. N Engl J Med 2011; 364: 907-917.
56. Moura IC, Centelles MN, Arcos-Fajardo M et al. Identification of the transferrin receptor as a novel immunoglobulin (Ig)A1 receptor and its enhanced expression on mesangial cells in IgA nephropathy. J Exp Med 2001; 194: 417-425.
57. Raska M, Moldoveanu Z, Suzuki H et al. Identification and characterization of CMP-NeuAc:GalNAc-IgA1 a2,6-sialyltransferase in IgA1-producing cells. J Mol Biol 2007; 369: 69-78.
58. Novak J, Vu HL, Novak L et al. Interactions of human mesangial cells with IgA and IgA-containing immune complexes. Kidney Int 2002; 62: 465-475.
59. Novak J, Moldoveanu Z, Renfrow MB et al. IgA nephropathy and Henoch- Schoenlein purpura nephritis: aberrant glycosylation of IgA1, formation of IgA1-containing immune complexes, and activation of mesangial cells. Contrib Nephrol 2007; 157: 134-138.
60. Renfrow MB, Cooper HJ, Tomana M et al. Determination of aberrant O-glycosylation in the IgA1 hinge region by electron capture dissociation fourier transform-ion cyclotron resonance mass spectrometry. J Biol Chem 2005; 280: 19136-19145.
61. Renfrow MB, Mackay CL, Chalmers MJ et al. Analysis of O-glycan heterogeneity in IgA1 myeloma proteins by Fourier transform ion cyclotron resonance mass spectrometry: implications for IgA nephropathy. Anal Bioanal Chem 2007; 389: 1397-1407.
62. Gomes MM, Suzuki H, Brooks MT et al. Recognition of galactose-deficient O-glycans in the hinge region of IgA1 by N-acetylgalactosamine-specific snail lectins: a comparative binding study. Biochemistry 2010; 49: 5671-5682.
63. .Novak J, Raskova Kafkova L, Suzuki H et al. IgA1 immune complexes from pediatric pat ients with IgA nephropathy activate cultured human mesangial cells. Nephrol Dial Transplant 2011; 26: 3451-3457.
64. Lebron JA, Bennett MJ, Vaughn DE et al. Crystal structure of the hemochromatosis protein HFE and characterization of its interaction with transferrin receptor. Cell 1998; 93: 111-123.
65. Tissandie E, Morelle W, Berthelot L et al. Both IgA nephropathy and alcoholic cirrhosis feature abnormally glycosylated IgA1 and soluble CD89-IgA and IgG-IgA complexes: common mechanisms for distinct diseases. Kidney Int 2011; 80: 1352-1363.
66. Eitner F, Floege J. Glomerular disease: the Oxford classification- predicting progression of IgAN. Nat Rev Nephrol 2009; 5: 557-559.